Irinotecan: A new antineoplastic agent for the management of colorectal cancer

Annals of Pharmacotherapy

Volumn 32, Issue 12, 1998, Pages 1324-1333

  Cersosimo, Robert J ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Cancer; Colorectal; Irinotecan; Lung

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DEXAMETHASONE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANISETRON; IRINOTECAN; NAVELBINE; ONDANSETRON; PACLITAXEL; SEROTONIN ANTAGONIST; VINDESINE;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; VOMITING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEUTROPENIA;

EID: 0032411767     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17462     Document Type: Review

References (6)

1. Gottlieb JA, Guarino AM, Call JB, Oliverio V, Block J. Preliminary pharmacokinetic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 1970;54:461-70.
2. Schaeppi V, Fleischman RW, Cooney DA. Toxicity of camptothecin (NSC-100880). Cancer Chemother Rep 1974;58:25-36.
3. Takimoto CH, Arbuck SG. Tlie camptothecins. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy. 2nd ed. Philadelphia: Lippincott-Raven, 1996:463-84.
4. Package insert. Camptosar (irinotecan). Kalamazoo, MI: Pharmacia & Upjohn Co., December 1997.
5. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular role of SN-38, a metabolite of the camptothecin derivative, CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
6. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen T-L, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyI 1-1 0-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin (CPT-11) administered as a ninety-minute infusion even' 3 weeks. Cancer Res 1994:54:427-36.